PubRank
Search
About
M A Villalona-Calero
Author PubWeight™ 20.38
‹?›
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer.
Ann Oncol
2002
2.42
2
Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors.
J Clin Oncol
1999
1.56
3
Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity.
Ann Oncol
2002
1.51
4
Increased expression of unmethylated CDKN2D by 5-aza-2'-deoxycytidine in human lung cancer cells.
Oncogene
2001
1.30
5
Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors.
Br J Cancer
2005
1.11
6
Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer.
Cancer Chemother Pharmacol
2012
1.03
7
Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors.
Ann Oncol
1998
0.97
8
A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer.
Ann Oncol
2004
0.96
9
Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors.
J Clin Oncol
1999
0.95
10
Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.
Ann Oncol
2001
0.91
11
Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies.
Cancer Chemother Pharmacol
2008
0.84
12
A phase I clinical and pharmacokinetic study of fenretinide combined with paclitaxel and cisplatin for refractory solid tumors.
Invest New Drugs
2005
0.84
13
Extragonadal abdominal germ cell cancers.
Am J Clin Oncol
1992
0.81
14
An epigenetic mechanism for capecitabine resistance in mesothelioma.
Biochem Biophys Res Commun
2009
0.80
15
Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.
J Clin Oncol
2000
0.79
16
RT-PCR heteroduplex analysis permits differentiation of transgene and host gene expression in a transgenic animal model.
Biotechniques
2002
0.78
17
Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies.
J Clin Oncol
2000
0.78
18
Alternative dosing schedules for irinotecan.
Oncology (Williston Park)
1998
0.77
19
A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors.
Clin Cancer Res
1999
0.76
20
Secondary acute myelogenous leukemia in children with Latin-American ancestry.
J Clin Oncol
1993
0.75
21
Acute progranulocytic leukemia (APL): possible in vivo differentiation by granulocyte colony-stimulating factor (G-CSF)
Leukemia
1993
0.75